Comparative Pharmacology
Head-to-head clinical analysis: EVOMELA versus MELPHALAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOMELA versus MELPHALAN HYDROCHLORIDE.
EVOMELA vs MELPHALAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
None Documented
None Documented
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Category C
Category D/X
Alkylating Agent
Alkylating Agent